Monthly Archives: August 2012

A Silver Lining to Sola?

The headlines for the Phase III topline results for Lilly‘s solanezumab were pretty much the same as for bapineuzemab: Primary endpoints were missed, and by that definition, the Phase III program was a failure. But there was a very ambiguous … Continue reading

Posted in Uncategorized | Tagged , , , , | Leave a comment

Elan Corporation: 1969-2013

Elan has announced that it will spin off Neotope Biosciences as a repository of all its preclinical/discovery research–devoted to targeting rogue proteins (amyloid, tau, synuclein) in the treatment of neurodegeneration. Elan’s longterm CSO, Dale Schenk, is the CEO; Elan intends … Continue reading

Posted in Uncategorized | Tagged , , , , | 1 Comment

RIP BAPI

The other bapi shoe has now dropped, with the first non-ApoE4 Phase III top line results showing nothing, nothing at all. The IV bapineuzumab program has been discontinued, with two Phase III trials yet to report, but certain to do … Continue reading

Posted in Uncategorized | Tagged , , | 1 Comment